MESO Q2 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+5.3% YoY

Gross Profit

-$17M-880.1% margin

Operating Income

-$24M-1204.5% margin

Net Income

-$25M-1248.6% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-88.3%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$690M

Total Liabilities

$189M

Stockholders' Equity

$501M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+5.3%
Gross Profit	-$17M	-$4M	-390.8%
Operating Income	-$24M	-$24M	+2.0%
Net Income	-$25M	-$25M	+0.1%